Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK

A method for inhibition of JAK2 and/or JAK3 in a subject suffering from a disease associated with JAK2 and/or JAK3, the method comprising administering to the subject a compound of formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• G1 is selected from the group consisting of CR8;
• R1 is selected from the group consisting of optionally substituted C3-8 cycloalkyl, optionally substituted C3-6 heterocycloalkyl, optionally substituted C4-14 aryl, optionally substituted C1-10 heteroaryl, and optionally substituted C1-6 alkyl;
• R2 and R3 are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl, or R2, R3, and the carbon atom to which they are attached form a carbonyl;
• R4 is selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, optionally substituted C1-4 alkoxy, halo, hydroxy, and amino;
• R5 is selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, and halo;
• R6 and R7 are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl, or R6, R7, and the carbon atom to which they are attached form a carbonyl;
• R8 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkoxy, C1-9 amide, C1-5 oxycarbonyl, cyano, optionally substituted C3-8 cycloalkyl, optionally substituted C4-14 aryl, optionally substituted C1-10 heteroaryl, and halo;
• and
• with the proviso that no more than one carbonyl is formed from R2 and R3 and R6 and R7.